Verastem
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 73
- Market Cap
- -
- Website
- http://www.verastem.com
- Introduction
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06682572
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
🇯🇵Mie University Hospital, Tsu, Mie, Japan
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- 🇺🇸
Texas Oncology Central, Austin, Texas, United States
🇺🇸Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05669482
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT05375994
- Locations
- 🇺🇸
UCSF Thoracic Oncology, San Francisco, California, United States
🇺🇸University of Colorado Hospital Anschutz Cancer Pavllion, Aurora, Colorado, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Food Effect of VS-6766 in Healthy Adult Subjects
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05187169
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT05074810
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, LLP, Boulder, Colorado, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,, Washington, District of Columbia, United States
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT04625270
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Sansum Clinic, Santa Barbara, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04620330
- Locations
- 🇺🇸
Hematology/Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Illinois Cancer Specialists, Niles, Illinois, United States
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02943317
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute (FCS), Sarasota, Florida, United States
🇺🇸Dana Farber Cancer Instiyute, Boston, Massachusetts, United States
🇺🇸Stephenson Cancer Center (University of Oklahoma), Oklahoma City, Oklahoma, United States
A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02913716